A case of nivolumab-induced scleroderma-like syndrome successfully treated with intravenous immunoglobulin

Checkpoint inhibitors are monoclonal antibodies used in cancer therapy to stimulate the immune system’s antitumor activity by preventing T-cell inhibition through targets such as PD-1/PD-L1 and CTLA-4. The increased immune activity is not tumor-specific, and immune-related adverse events (irAEs) are common. Cutaneous reactions are some of the most frequent irAEs described, making up a broad spectrum of reactions, including acneiform, lichenoid, psoriasiform, and immunobullous eruptions,1,2 as well as rare checkpoint inhibitor-induced morphea or scleroderma-like syndrome (SLS).